Related Experiment Video

Updated: Jun 27, 2025

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes
11:03

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

3.9K

Correction: Deoxycholic acid supplementation impairs glucose homeostasis in mice

Karolina E Zaborska, Seon A Lee, Darline Garibay

    Plos One
    |May 1, 2024
    PubMed

    More Related Videos

    Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

    Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

    Published on: March 11, 2017

    16.0K
    Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

    Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

    Published on: January 7, 2018

    68.3K

    Related Concept Videos

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are...
    174
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    181
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    319